stockportfolio.pro
Stocks / PCRX vs QDEL
PCRX vs QDEL
Pacira BioSciences, Inc. and QuidelOrtho Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Pacira BioSciences, Inc. (PCRX) | QuidelOrtho Corporation (QDEL) | |
|---|---|---|
| Market cap | $0.9B | $0.9B |
| Revenue (latest FY) | $726.41M | $2.73B |
| Net income (latest FY) | $7.03M | $-1.13B |
| Revenue growth (5y CAGR) | 11.1% | 10.4% |
| Net margin | 1.0% | -41.5% |
| Return on equity | 1.0% | -58.9% |
| P/E ratio | 180.3 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 3 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open PCRX — free Open QDEL — freeFrequently asked questions
Which is bigger, PCRX or QDEL?
QuidelOrtho Corporation is larger by market capitalization — $0.9B versus $0.9B.
Which grows faster, PCRX or QDEL?
Over the last five fiscal years, Pacira BioSciences, Inc. grew revenue faster — 11.1%/yr versus 10.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.